tefibazumab
mAbexperimental
Tefibazumab is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis and of methicillin-resistant S. aureus. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2005 (NCT00198289)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Clumping factor AINHIBITOR
clfA inhibitor
- Staphylococcus aureusImmunity, passive
Staphylococcus aureus immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTefibazumab ↗
- ChEMBLCHEMBL2108055 ↗
Also known as
- aurexis
- aurexis
- inh-h2002
- tefibazumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00198302 | Phase 2 | Sep 9, 2005 | Bristol-Myers Squibb, Inhibitex |
| NCT00198289 | Phase 2 | Apr 1, 2005 | Bristol-Myers Squibb, Inhibitex |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 2 | 2 | 1 | 2005 |
| Inhibitex | For profit | 2 | 0 | 1 | 2005 |
2 organizations
Page 1 / 1